Sorafenib enhanced survival in advanced thyroid cancer

  • April 24, 2014

Sorafenib significantly extended progression-free survival and appeared tolerable in patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer, according to phase 3 study results.

The multicenter, double-blind DECISION trial included 417 patients who had progressed within the previous 14 months.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

  • Editorial
  • Editor Pick 1
  • Adrenal cancer and research
  • Gary D. Hammer, MD, PhD, writes about research and collaboration to make a differnce with adrenal cancer.
More »
  • Health Care Update
  • Medicare lab payments
  • New law will modernize Medicare lab payments: What physicians need to know. Analysis from Arnold & Porter LLP.
More »
More »
  • MedBlog
  • Editor Pick 3
  • Memories
  • Visit MedBlog to see the latest post from Michael Kleerekoper, MD, MACE.
More »
More »
  • Financial Planning
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »